X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs GLENMARK PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES GLENMARK PHARMA PIRAMAL ENTERPRISES/
GLENMARK PHARMA
 
P/E (TTM) x 10.4 25.3 41.2% View Chart
P/BV x 1.8 4.0 45.3% View Chart
Dividend Yield % 0.9 0.3 297.9%  

Financials

 PIRAMAL ENTERPRISES   GLENMARK PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
GLENMARK PHARMA
Mar-17
PIRAMAL ENTERPRISES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,083993 310.5%   
Low Rs1,902729 260.8%   
Sales per share (Unadj.) Rs589.7325.5 181.2%  
Earnings per share (Unadj.) Rs284.039.3 722.8%  
Cash flow per share (Unadj.) Rs310.548.7 638.1%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %1.00.2 431.9%  
Book value per share (Unadj.) Rs1,467.0159.2 921.4%  
Shares outstanding (eoy) m180.27282.17 63.9%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x4.22.6 159.8%   
Avg P/E ratio x8.821.9 40.0%  
P/CF ratio (eoy) x8.017.7 45.4%  
Price / Book Value ratio x1.75.4 31.4%  
Dividend payout %8.85.1 172.9%   
Avg Mkt Cap Rs m449,332242,991 184.9%   
No. of employees `0006.813.0 52.8%   
Total wages/salary Rs m19,88116,408 121.2%   
Avg. sales/employee Rs Th15,535.67,083.9 219.3%   
Avg. wages/employee Rs Th2,905.41,265.4 229.6%   
Avg. net profit/employee Rs Th7,482.5855.1 875.1%   
INCOME DATA
Net Sales Rs m106,31091,857 115.7%  
Other income Rs m2,595374 694.6%   
Total revenues Rs m108,90692,230 118.1%   
Gross profit Rs m51,59920,367 253.3%  
Depreciation Rs m4,7732,644 180.6%   
Interest Rs m29,7832,373 1,255.0%   
Profit before tax Rs m19,63815,724 124.9%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m-28,7643,827 -751.7%   
Profit after tax Rs m51,20311,088 461.8%  
Gross profit margin %48.522.2 218.9%  
Effective tax rate %-146.524.3 -601.8%   
Net profit margin %48.212.1 399.0%  
BALANCE SHEET DATA
Current assets Rs m118,15468,746 171.9%   
Current liabilities Rs m462,26027,027 1,710.4%   
Net working cap to sales %-323.745.4 -712.7%  
Current ratio x0.32.5 10.0%  
Inventory Days Days2785 31.3%  
Debtors Days Days4796 48.7%  
Net fixed assets Rs m113,72724,132 471.3%   
Share capital Rs m361282 127.7%   
"Free" reserves Rs m264,09344,643 591.6%   
Net worth Rs m264,45444,925 588.7%   
Long term debt Rs m242,20645,363 533.9%   
Total assets Rs m726,834117,639 617.9%  
Interest coverage x1.77.6 21.8%   
Debt to equity ratio x0.91.0 90.7%  
Sales to assets ratio x0.10.8 18.7%   
Return on assets %11.111.4 97.4%  
Return on equity %19.424.7 78.5%  
Return on capital %10.319.1 53.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11056,152 26.9%   
Fx outflow Rs m4,2988,084 53.2%   
Net fx Rs m10,81348,068 22.5%   
CASH FLOW
From Operations Rs m-159,6666,574 -2,428.6%  
From Investments Rs m-17,677-7,124 248.2%  
From Financial Activity Rs m186,5035,432 3,433.7%  
Net Cashflow Rs m9,3641,992 470.0%  

Share Holding

Indian Promoters % 52.9 48.3 109.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 6.9 58.0%  
FIIs % 26.6 34.4 77.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.5 157.1%  
Shareholders   93,274 56,727 164.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   SUVEN LIFE  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 21, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS